Scarica l'app Stockscreener
3.34
3.34%
0.05
Precedente Chiudi:
$3.29
Aprire:
$3.46
Volume 24 ore:
45,082
Relative Volume:
1.41
Capitalizzazione di mercato:
$142.48M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-30.61%
1M Prestazione:
-38.52%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.99
$3.46
Intervallo di 1 settimana:
$2.92
$4.84
Portata 52W:
$2.92
$6.2324
Tuhura Biosciences Inc Stock (HURA) Company Profile
Nome
Tuhura Biosciences Inc
Settore
Industria
Telefono
813-875-6600
Indirizzo
10500 UNIVERSITY CENTER DR., TAMPA
Confronta HURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| HURA | 3.26 | 142.48M | 0 | 0 | 0 | 0.00 |
| VRTX | 449.74 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.06 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.25 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.30 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Tuhura Biosciences Inc Borsa (HURA) Ultime notizie
TuHURA Biosciences Announces Executive Salary and Stock Options - TipRanks
TuHURA Biosciences Inc (HURA) Quarterly 10-Q Report - Quartzy
TuHURA Biosciences Inc expected to post a loss of 10 cents a shareEarnings Preview - XM
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - AccessWire
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event - AccessWire
TuHURA Biosciences finalizes merger, sets Phase 3 trial - Investing.com India
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 - PR Newswire
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
Lowenstein Represents Kintara Therapeutics in Merger with TuHURA Biosciences - Lowenstein Sandler LLP
TuHURA Biosciences finalizes merger, sets Phase 3 trial By Investing.com - Investing.com South Africa
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics - Yahoo Finance
Kintara Therapeutics Announces Stock Split Amid Merger - TipRanks
Kintara approves reverse stock split, rebrands as TuHURA Biosciences - Investing.com India
Kintara announces 1-for-35 reverse stock split in connection with TuHURA merger - TipRanks
Kintara approves 1-for-35 reverse stock split before merger - Investing.com
Kintara approves 1-for-35 reverse stock split before merger By Investing.com - Investing.com South Africa
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 - StockTitan
Kintara approves reverse stock split, rebrands as TuHURA Biosciences By Investing.com - Investing.com Australia
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - Quantisnow
Kintara amends CVR issuance terms ahead of TuHURA merger By Investing.com - Investing.com Canada
Kintara amends CVR issuance terms ahead of TuHURA merger - Investing.com India
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024 - StockTitan
Kintara stock climbs 10% on TuHURA merger update (NASDAQ:KTRA) - Seeking Alpha
Kintara Therapeutics Set for Strategic Merger and CVR Issuance - TipRanks
Stockholders Fail to Approve Proposal to Reincorporate Nevada Corporation in Delaware - The National Law Review
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update - StockTitan
Kintara shareholders approve key proposals; Charter change fails By Investing.com - Investing.com UK
Kintara shareholders approve key proposals; Charter change fails - Investing.com
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1 - StockTitan
Kintara Therapeutics modifies merger terms with TuHURA Biosciences - Investing.com
Kintara Urges Shareholder Votes for TuHURA Biosciences Merger - TipRanks
Kintara Therapeutics Seeks Approval for Key Merger with TuHURA Biosciences - TipRanks
Kintara Announces Special Meeting for Proposed TuHURA Merger - TipRanks
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences | KTRA Stock News - StockTitan
Kintara Therapeutics Advances with TuHURA Merger and Trials - TipRanks
Kintara Therapeutics Calls for Vote on TuHURA Merger - TipRanks
Kintara Therapeutics announces special meeting details By Investing.com - Investing.com Australia
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer - PR Newswire
Kintara Therapeutics restructures share designations - Investing.com
Kintara Therapeutics Eyes Acquisition Amidst Cautionary Advice - TipRanks
Kintara and TuHURA announce merger and clinical progress - Investing.com
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carci - PR Newswire
Laurel Lee from Florida's 15th district invests in TuHURA Biosciences By Investing.com - Investing.com
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results - PR Newswire
Wolfe Research cuts Warner Bros Discovery stock to underperform By Investing.com - Investing.com Nigeria
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc.KTRA - PR Newswire
Kintara and TuHURA in merger deal to advance oncology pipeline - Pharmaceutical Technology
Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today? - InvestorPlace
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab - PR Newswire
Kintara Therapeutics And TuHURA Biosciences To Merge - Contract Pharma
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer - PR Newswire
Tuhura Biosciences Inc Azioni (HURA) Dati Finanziari
Non sono disponibili dati finanziari per Tuhura Biosciences Inc (HURA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):